The Molecular Profiling Institute named US provider of genetic breast cancer test

December 08, 2004

Phoenix, AZ, December 8, 2004--The Molecular Profiling Institute (MPI), today announced that it is the sole source provider in the United States for MammaPrint®. MammaPrint® is a prognostic test developed by Agendia that helps identify how a breast cancer patient's tumor will behave. MPI in collaboration with the Netherlands-based Agendia, and AmeriPath will offer MammaPrint® through physician referral to breast cancer patients nationwide beginning in January 2005.

MammaPrint® employs gene expression profiling to assess the recurrence risk in breast cancer patients. Oncologists receive detailed prognostic information on women with primary invasive breast cancer aged 55 years or younger who are lymph node negative with either a positive or negative estrogen receptor status. Taken together with a patient's clinical information this test may provide valuable assistance for oncologists in formulating tailor-made treatment plans.

Approximately 70 percent of the 250,000 patients diagnosed annually with breast cancer are stage I and II. Nearly 50 percent of affected women are under age 60. The test has the potential to add positively to the clinical decisions influencing nearly 70,000 breast cancer patients per year.

Using the MammaPrint® microarray assay, MPI can determine which genes are expressed in a breast cancer patient's tumor. The tumor is then classified as "good" prognosis or "poor" prognosis. The results allow oncologists to implement a more effective and personalized treatment plan.

Typically, oncologists use several clinical factors --age, estrogen receptor status, tumor size and grade-- to determine how a patient's tumor will behave and how best to intervene. When compared to these clinical factors, the MammaPrint® test has been shown to provide the most comprehensive prognostic information assessing the development of future metastases.

A patient-tailored treatment plan based on the genetics of the tumor combined with standard prognostic information enables physicians to more accurately define patients who will benefit from therapy.

"We believe that the MammaPrint® test will provide an important first step for physicians to ultimately bring personalized medicine to the nation's breast cancer patients," said Robert J. Penny MD, PhD, President and CEO of MPI.

Large-scale prospective clinical trials of MammaPrint® are currently underway led by the Netherlands Cancer Institute in some 10,000 breast cancer patients to further validate the breast cancer prognosis signature.

"We are very excited with the external validation of the MammaPrint® test by six independent medical centers," said Dr. Bernhard Sixt, CEO and co-founder of Agendia. "Our strategic partnership with MPI will ensure that US patients and the medical community have access to MammaPrint®."

Additionally, MPI and AmeriPath have formed a partnership where AmeriPath's pathologist network will have access to the molecular profiling provided by MPI. AmeriPath will use MPI as their advanced esoteric reference lab.

"AmeriPath's partnership with MPI will allow our pathologists to continue to be national leaders in the delivery of premier diagnostic testing and healthcare information to the 3.5 million community of patients that we serve," said Jeffrey Mossler, MD, Chief Medical Officer of AmeriPath.

The MammaPrint® test will be available in January 2005. MPI is the sole provider of MammaPrint® in the United States. For further information regarding MammaPrint® contact MPI at 602-358-8900 or

This test was developed and its performance characteristics determined by Agendia. It has not been cleared or approved by the US Food and Drug Administration. The FDA ha determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. The laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.
About MPI

The Molecular Profiling Institute, Inc. (MPI) is a specialty reference laboratory that helps cancer patients worldwide by applying the discoveries of the Human Genome Project to personalized medicine. MPI provides cutting-edge testing facilities, products, and resources for genomic and proteomic profiling and treatment of cancers. The Molecular Profiling Institute, Inc., has strategic relationships with the Translational Genomics Research Institute (TGen) and Ameripath. For additional information, please visit the MPI web site at

About Agendia

Agendia was established in 2003 to develop new prognostic tools, based on gene expression profiling, to be used in oncology. Agendia has its roots in the Netherlands Cancer Institute, an internationally renowned cancer research center. Agendia's first commercialized product is a breast cancer prognostic test called MammaPrint®. The company, located in Amsterdam, The Netherlands, has a high quality laboratory for patient testing. Several large-scale clinical studies are ongoing in hospitals in Europe and the US to further validate MammaPrint® in a large and diverse patient population. For additional information, please visit the Agendia web site at

The Translational Genomics Research Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to